ELIGARD PACKAGE INSERT PDF

  • No Comments

ELIGARD (leuprolide acetate) is indicated for the palliative due to incorrect reconstitution or administration of the product (see Monitoring and Laboratory .. Gently insert the long, white replacement plunger rod into the gray. PACKAGE LEAFLET: INFORMATION FOR THE USER. ELIGARD 45 mg powder and solvent for solution for injection. Leuprorelin acetate. Read all of this leaflet. Eligard® is a sterile polymeric matrix formulation of leuprorelin acetate for subcutaneous package insert for constitution and administration procedures.

Author: JoJokus Shakarn
Country: Czech Republic
Language: English (Spanish)
Genre: Music
Published (Last): 24 September 2009
Pages: 372
PDF File Size: 18.12 Mb
ePub File Size: 9.5 Mb
ISBN: 620-9-20675-967-3
Downloads: 29291
Price: Free* [*Free Regsitration Required]
Uploader: Gakree

Screw the white plunger into the end stopper until the stopper begins to turn. HCG is then administered to induce final follicular maturation for oocyte retrieval. Hold syringe Inxert upright.

Oops Something Went Wrong!

Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and with close monitoring with leuprolide include gemifloxacin. Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and with close monitoring with leuprolide include romidepsin.

According to the manufacturer, concurrent use of citalopram with other drugs that prolong the QT interval is not recommended.

Clinical trial data indicate that ziprasidone causes QT prolongation; there are postmarketing reports of torsade de pointes TdP in patients packae multiple confounding factors.

Case reports indicate that QT prolongation and torsade de pointes TdP can occur during donepezil therapy. Eligwrd analog therapy increases the risk of reduced bone mineral density in men as well as women, and may have particular relevance for the geriatric population. In one study, a single mean dose of 5.

  JERZY PARYSEK PDF

Cases of QT prolongation and TdP have been reported during postmarketing use of fluvoxamine. Remove the pink cap on the bottom of the sterile needle cartridge. Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and with close monitoring with leuprolide include telavancin. For the monthly, three 3 month, four 4 month, and six 6 month depot formulations: Major Although data are limited, coadministration of efavirenz and leuprolide may increase the risk for QT prolongation and torsade de pointes TdP.

Seizures have been reported during postmarketing surveillance in elugard with a history of epilepsy, cerebrovascular disease, central nervous system anomalies or brain tumor, and patients on concomitant medications that have been associated with seizures. While the Lupron Depot-Ped product is indicated for packaage in children, the Viadur inserg and Eligard brands of leuprolide are contraindicated in children and adolescents due to limited experience.

Drugs with a possible risk for QT prolongation and TdP inert should be pacakge cautiously and with close monitoring with arsenic trioxide include leuprolide Androgen deprivation therapy e. Leuprolide should only be used by a qualified infertility specialist. Because of the potential for QT prolongation and torsade de pointes TdPuse of terfenadine, a drug with an established risk for TdP, with leuprolide is contraindicated.

Emtricitabine; Rilpivirine; Tenofovir alafenamide: QT prolongation has been observed with use of efavirenz.

Because the consequences on lactation and to the nursing infant are not known, breast-feeding should be avoided during treatment with leuprolide. Major The concomitant use of midostaurin and leuprolide may lead to additive QT interval prolongation.

  AUSLANDSREISEPAUSCHALEN 2014 PDF

Eligard (leuprolide acetate) dose, indications, adverse effects, interactions from

Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and with close monitoring with leuprolide elifard ibutilide.

Quetiapine is associated with a possible risk for QT prolongation and TdP and should be used cautiously and with close monitoring with leuprolide. This effect may be additive to other drugs that may cause QT prolongation. An interruption of therapy, dose reduction, or discontinuation of therapy may be necessary for crizotinib if QT prolongation occurs.

Allow the product to reach room temperature before mixing. Major Monitor patients for QT prolongation if coadministration of leuprolide with sunitinib is necessary. After injection, withdraw the needle from the injection site. After reconstitution, the suspension settles very quickly; therefore, mix and administer the suspension immediately. For all Depot-Ped formulations: Clinicians should consult the appropriate references to verify the dose.

Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and with close monitoring with leuprolide include paliperidone. Because of the potential for TdP, use of halofantrine with leuprolide is contraindicated. Subcutaneous dosage solution for injection.

Intramuscular injection depot suspension.